Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | GAA | P10253 | 4/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL872190 | 0.86 | PTGS1 (0.68) | PTGS1PTGS2MAPK1SMN1; SMN2CYP1A2 | |
| SCHEMBL23387882 | 0.83 | PTGS1 (0.65) | PTGS1PTGS2MAPK1SMN1; SMN2CYP1A2 | |
| SCHEMBL2447965 | 0.83 | PTGS1 (0.65) | PTGS1PTGS2MAPK1SMN1; SMN2CYP1A2 | |
| SCHEMBL118913 | 0.83 | PTGS1 (0.65) | PTGS1PTGS2MAPK1SMN1; SMN2CYP1A2 | |
| SCHEMBL118200 | 0.83 | PTGS1 (0.65) | PTGS1PTGS2MAPK1SMN1; SMN2CYP1A2 | |
| SCHEMBL12441268 | 0.82 | PTGS1 (0.64) | PTGS1PTGS2MAPK1SMN1; SMN2CYP1A2 | |
| SCHEMBL1445392 | 0.82 | NPC1 (0.56) | PTGS1PTGS2MAPK1SMN1; SMN2NTRK1 | |
| SCHEMBL3082062 | 0.82 | PTGS1 (0.64) | PTGS1PTGS2MAPK1SMN1; SMN2CYP1A2 | |
| SCHEMBL31312607 | 0.82 | PTGS1 (0.64) | PTGS1PTGS2MAPK1SMN1; SMN2CYP1A2 | |
| Hydrochloric Acid SCHEMBL2218615 | 0.81 | PTGS1 (0.62) | PTGS1PTGS2MAPK1SMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070922-A1 | PYRAZOLE AND IMIDAZOLE DERIVATIVES AS DUAL OREXIN AND KAPPA-OPIOID RECEPTORS MODULATORS COMPOSITION, METHODS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | HAGER BIOSCIENCES, LLC (US) | 2026-03-12 | — | — | US | disclosed |
| US-11780837-B2 | CXCR4 inhibitors and uses thereof | X4 PHARMACEUTICALS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780837-B2 | CXCR4 inhibitors and uses thereof | X4 PHARMACEUTICALS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| EP-3808748-A1 | SUBSTITUTED PIPERIDINES AS CXCR4-INHIBITORS | X4 Pharmaceuticals, Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3471727-B1 | CXCR4 INHIBITORS AND USES THEREOF | X4 PHARMACEUTICALS INC (US) | 2020-12-09 | — | — | EP | disclosed |
| US-20170369511-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2017-12-28 | — | — | US | disclosed |
| US-9708348-B2 | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708348-B2 | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9403847-B2 | Substituted heteroaryl fused derivatives as P13K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403847-B2 | Substituted heteroaryl fused derivatives as P13K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-08-02 | — | — | US | disclosed |
| US-20110190319-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-08-04 | — | — | US | disclosed |
| WO-2011075643-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011075643-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-06-23 | — | — | WO | disclosed |
| WO-2010126745-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS β-SECRETASE INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20060014746-A1 | Heteroaryl substituted fused bicyclic heteroaryl compounds as GABAA receptor ligands | NEUROGEN CORPORATION | 2006-01-19 | — | — | US | disclosed |
| US-6936617-B2 | Heteroaryl substituted fused bicyclic heteroaryl compound as GABAA receptor ligands | NEUROGEN CORPORATION (US) | 2005-08-30 | — | — | US | disclosed |
| EP-1406906-A1 | HETEROARYL SUBSTITUTED FUSED BICYCLIC HETEROARYL COMPOUNDS AS GABAA RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030207885-A1 | Heteroaryl substituted fused bicyclic heteroaryl compound as GABAA receptor ligands | NEUROGEN CORPORATION | 2003-11-06 | — | — | US | disclosed |
| WO-2003006471-A1 | HETEROARYL SUBSTITUTED FUSED BICYCLIC HETEROARYL COMPOUNDS AS GABAA RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2003-01-23 | — | — | WO | disclosed |
| WO-2003006471-A1 | HETEROARYL SUBSTITUTED FUSED BICYCLIC HETEROARYL COMPOUNDS AS GABAA RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190319-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3R5 | PTGS1 776/4885PTGS2 925/4885MAPK1 241/4885 |
| US-20060014746-A1 | Heteroaryl substituted fused bicyclic heteroaryl compounds as GABAA receptor ligands | GABRA5, GABRA2, GABBR1 | PTGS1 2603/4885PTGS2 1302/4885MAPK1 4600/4885 |
| US-20170369511-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PTGS1 1405/4885PTGS2 1742/4885MAPK1 186/4885 |
| US-11780837-B2 | CXCR4 inhibitors and uses thereof | CXCR4, CXCL12, CXCR3 | PTGS1 1523/4885PTGS2 2186/4885MAPK1 1694/4885 |
| US-20030207885-A1 | Heteroaryl substituted fused bicyclic heteroaryl compound as GABAA receptor ligands | GABRA5, GABRA2, GABBR1 | PTGS1 2192/4885PTGS2 1280/4885MAPK1 4466/4885 |
| US-20260070922-A1 | PYRAZOLE AND IMIDAZOLE DERIVATIVES AS DUAL OREXIN AND KAPPA-OPIOID RECEPTORS MODULATORS COMPOSITION, METHODS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | OPRK1, OPRD1, HCRTR2 | PTGS1 1448/4885PTGS2 2159/4885MAPK1 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.